Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Carcinoma, Basal Cell
|
91 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.030 | 0.667 | 3 | 1999 | 2005 | |||||
Experimental Organism Basal Cell Carcinoma
|
63 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.030 | 0.667 | 3 | 1999 | 2005 | |||||
Xeroderma Pigmentosum, Complementation Group D
|
111 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.938 | 32 | 2001 | 2019 | |||||
Malignant Neoplasms
|
1641 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.909 | 11 | 2002 | 2015 | |||||
Primary malignant neoplasm
|
1374 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.090 | 0.889 | 9 | 2002 | 2015 | |||||
Squamous cell carcinoma of esophagus
|
329 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.040 | 1.000 | 4 | 2002 | 2012 | |||||
Carcinoma of lung
|
1204 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.800 | 0.963 | 27 | 2003 | 2019 | |||||
Malignant neoplasm of lung
|
1142 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.962 | 26 | 2003 | 2019 | |||||
Primary malignant neoplasm of lung
|
981 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.962 | 26 | 2003 | 2019 | |||||
Breast Carcinoma
|
2793 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.842 | 19 | 2004 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.842 | 19 | 2004 | 2019 | |||||
Malignant neoplasm of prostate
|
1082 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.070 | 0.857 | 7 | 2004 | 2017 | |||||
Prostate carcinoma
|
1168 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.070 | 0.857 | 7 | 2004 | 2017 | |||||
Congenital chromosomal disease
|
47 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.030 | 1.000 | 3 | 2004 | 2012 | |||||
Skin carcinoma
|
24 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.030 | 0.667 | 3 | 2004 | 2014 | |||||
Colorectal Carcinoma
|
1962 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 0.800 | 15 | 2005 | 2019 | |||||
Glioma
|
353 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.100 | 1.000 | 11 | 2005 | 2017 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.750 | 8 | 2005 | 2016 | |||||
melanoma
|
515 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.875 | 8 | 2005 | 2018 | |||||
Neoplasms
|
1644 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.080 | 0.875 | 8 | 2005 | 2017 | |||||
Adenocarcinoma Of Esophagus
|
81 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.030 | 1.000 | 3 | 2005 | 2008 | |||||
Malignant neoplasm of skin
|
38 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.020 | 0.500 | 2 | 2005 | 2014 | |||||
Squamous cell carcinoma
|
257 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.020 | 1.000 | 2 | 2005 | 2009 | |||||
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
82 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.020 | 1.000 | 2 | 2005 | 2018 | |||||
Adenomatous Polyps
|
20 | 0.487 | 0.760 | 19 | 45351661 | stop gained | T/A;G | snv | 4.0E-06; 0.32 | 0.010 | 1.000 | 1 | 2005 | 2005 |